Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics (NASDAQ:SPRO) reported Q4 2023 earnings of $0.96 per share, surpassing the $(0.10) estimate by 1060%, and a 74.55% increase from last year's $0.55. Sales reached $73.524M, beating the $18.633M estimate by 294.58%, and marking a 54.98% increase from the previous year's $47.441M.
March 13, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spero Therapeutics reported a significant beat on both earnings per share and sales for Q4 2023, with EPS at $0.96 against a $(0.10) estimate and sales of $73.524M against an $18.633M estimate.
The substantial beat on both earnings per share and sales estimates for Q4 2023 indicates strong financial performance and operational efficiency, likely leading to increased investor confidence and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100